Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance - Wikidata - wikimedia - TriplyDB

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

http://www.wikidata.org/entity/Q28282963

about

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.Resistant mechanisms to BRAF inhibitors in melanoma The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer Melanoma and the Unfolded Protein Response Tumour Cell Heterogeneity Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells Other targeted drugs in melanoma Current State of Animal (Mouse) Modeling in Melanoma Research The influence of subclonal resistance mutations on targeted cancer therapy BRAF Mutation in Colorectal Cancer: An Update Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma Universes collide: combining immunotherapy with targeted therapy for cancer What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway Pathways and therapeutic targets in melanoma The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy Beyond BRAF: where next for melanoma therapy?Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series Targeted therapies in development for non-small cell lung cancer Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond Patient-derived xenograft models of breast cancer and their predictive power Preclinical mouse cancer models: a maze of opportunities and challenges.Non-Darwinian dynamics in therapy-induced cancer drug resistance.Orphan nuclear receptor TR3 acts in autophagic cell death via mitochondrial signaling pathway A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition Prioritizing therapeutic targets using patient-derived xenograft models Comprehensive suppression of all apoptosis-induced proliferation pathways as a proposed approach to colorectal cancer prevention and therapy Cancer stem cells: a systems biology view of their role in prognosis and therapy Real-time, aptamer-based tracking of circulating therapeutic agents in living animals.Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging Modeling Tumor Clonal Evolution for Drug Combinations Design Ancient genes establish stress-induced mutation as a hallmark of cancer Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma

P2860

Q24315032-4C33D64A-935A-4865-85E5-FA7BCA2B9BDF Q26739717-548936D5-5641-46E4-8CEF-CFE78A5439BE Q26744335-EB664181-A306-45CD-9B81-EA84557F2523 Q26747247-1D5F704B-9746-4204-98C4-536861826B30 Q26765426-E2AA2AD6-7302-4A16-A1FA-E3CCA53D12BB Q26765895-B8550F19-5936-4DFE-8A46-72C96DDB4A57 Q26766292-3C6CF0E3-E8A3-46F7-A96F-6CDD07DCD89A Q26767415-63BBA752-35DD-4863-8983-E6BC84A8D3F0 Q26772895-9C0945B0-5D60-472D-901B-CBFA35C17E6E Q26774625-C42CA5BE-3E8B-482E-B2D1-D500A3F1624C Q26775594-65019085-94E7-4192-8266-A8FFA4696A29 Q26781652-41FBCDC5-5524-4CAB-890C-ACD6BB3592A3 Q26781693-9145987C-97A3-4E97-8307-F94A1535C9B1 Q26781926-DDE63708-4147-475A-8A4B-50DDB346D0F6 Q26795510-019D5110-2546-44B0-9BE5-96FFB4D6E2C8 Q26795735-F6725C0F-B9EA-4E33-83B5-00B4DE942833 Q26799864-BCDDC77D-58A5-40C1-BBB6-EAF167B520AC Q26824310-74868B35-0EF6-4AB9-9B25-DE80ADB28294 Q26825316-1C5302F3-0ABE-4946-871E-D0D1AED56186 Q26825780-381856C9-1050-486E-9658-1E0D29F83257 Q26865736-8942F475-725E-4F13-966A-4EE742718E12 Q27004672-EFB2C7C8-D2AA-46E5-8749-F9E6DFD70A90 Q27006853-B5587A2B-61F8-4F47-A9BB-09F29C42DBF7 Q27015224-DCF04409-0CE0-4534-B8E4-E685F5C45137 Q27015875-B788EE1B-B212-41DE-A183-01FAA53238B3 Q27022852-6576F9AC-509B-4A6F-AE60-8178B92FC23F Q27026323-52455E7A-0741-4A62-9C53-2CB232A1127E Q27026531-0054FF3C-935E-4E09-B1C5-8DE9B709669C Q27322080-84951880-516A-4491-9983-AACB72FA2001 Q27324745-22C705B2-6176-4E57-B338-F99DC70D0C50 Q27687897-D5C56E3C-3340-42C4-B83C-F275B0054352 Q27852692-2C99ADE6-DD10-457E-ABAA-B69A7DD44A8D Q28083993-BBD279FC-FB30-4C1B-9499-D08F34DA59AC Q28542683-B373CA76-A446-4CBD-8DB2-8A65C3097271 Q33569712-BFD8D44E-BF0D-4463-8219-47992B6787D0 Q33570021-20095955-BD0A-44BE-BEEA-711039478A86 Q33588217-19009CD1-708D-4283-8B5A-B34C7C60CE92 Q33590430-B97FD0D5-7490-497F-9898-2E7882B48266 Q33602374-3761B102-4EA9-45C0-B91C-4ED7C9D61692 Q33610782-5A52A842-FF01-4018-8884-E79EF08342A4

P2860

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

http://www.wikidata.org/entity/Q28282963

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Modelling vemurafenib resistan ...... y to forestall drug resistance

@ast

Modelling vemurafenib resistan ...... y to forestall drug resistance

@en

Modelling vemurafenib resistan ...... y to forestall drug resistance

@nl

type

label

Modelling vemurafenib resistan ...... y to forestall drug resistance

@ast

Modelling vemurafenib resistan ...... y to forestall drug resistance

@en

Modelling vemurafenib resistan ...... y to forestall drug resistance

@nl

prefLabel

Modelling vemurafenib resistan ...... y to forestall drug resistance

@ast

Modelling vemurafenib resistan ...... y to forestall drug resistance

@en

Modelling vemurafenib resistan ...... y to forestall drug resistance

@nl

P1433

Q28282963-793AB97A-2F3A-43A2-AF47-45983C67378A

P1476

Q28282963-C96A0A19-A479-47CD-A62B-DA8E7E55A8CC

P2093

Q28282963-06425943-023F-4D22-BB51-E7640EC85DDD

Q28282963-42CAE1CA-227D-4752-9F5A-77C372484497

Q28282963-59E6AFB0-B0A8-4A30-BF7E-1D8CB61EB61D

Q28282963-6C87A1B7-E5E2-4F96-9013-3DFAE5BFE51E

Q28282963-7804B3D3-248C-453A-95CF-5B328A661A4D

Q28282963-B8D7F9AB-714A-4D21-A66D-41F055756362

Q28282963-D65B5F0C-5FDE-4623-BA8A-BD06AE0347C7

Q28282963-F30E7237-3554-45D3-B88E-B36FD0FF0650

P2860

Q28282963-0235F973-605F-4B23-A3D1-A1309AD7819D

Q28282963-06E57CDD-8DFE-46D3-A642-6B94F4EB62F8

Q28282963-1E058AB6-3D6E-4F98-9841-F835D0EF3ACF

Q28282963-2889BBB9-8833-4807-9870-9F56D2D86988

Q28282963-3CE29ECB-3763-42CF-ABC5-5A368CAAF669

Q28282963-50E44E1C-A27C-47DB-9392-581983C5EB26

Q28282963-5BF6EC5F-F9AF-4FA1-902A-A319711BD113

Q28282963-68D22D67-26CA-482F-87AB-7FB4BAE9F57B

Q28282963-6A8CB945-799D-48F8-AE76-FBD366E4ADF3

Q28282963-A35AB3D3-0272-45A8-AE8D-10A9550F34E0

P2888

Q28282963-72E1FE37-5CF0-4B73-838D-C51E3D7B7CB0

P304

Q28282963-953F3139-0627-4D67-AB1C-9F01AA0C7A1B

P31

Q28282963-2DE80C45-0728-4214-A3F6-48D826794AF2

P3181

Q28282963-0D9653A8-4FFB-48F0-B167-9CB612A978D3

P356

Q28282963-C3A3E29A-ADF4-4C12-99D9-F7F2DAA9248C

P407

Q28282963-D508069A-E192-42CE-888D-3296C8513251

P433

Q28282963-4EC4E693-3F39-4FEC-B8F0-0CBE085857A1

P478

Q28282963-DD6E0A7A-5FEE-450D-AD94-0F8714B2A494

P50

Q28282963-489156A6-29D1-4587-8102-EC9C3E2346F1

P577

Q28282963-20E7F834-46EC-4DF9-BB9E-5A1BC7202F35

P5875

Q28282963-BB10AE3B-B3B9-448E-8FEA-E5D82DD5FF83

P6179

Q28282963-995A3804-16A9-4AE3-936C-AB6E1947A650

P698

Q28282963-6AAB0920-4215-4C15-A2B4-12C6CB3AE5F4

P932

Q28282963-85190D7D-EDBF-4901-A409-5E5DC328CD49

P3181

P356

P1433

P1476

Modelling vemurafenib resistan ...... y to forestall drug resistance

@en

P2093

Allison S Landman

http://www.w3.org/2001/XMLSchema#string

Darrin D Stuart

http://www.w3.org/2001/XMLSchema#string

Fernando Salangsang

http://www.w3.org/2001/XMLSchema#string

Martin McMahon

http://www.w3.org/2001/XMLSchema#string

Meghna Das Thakur

http://www.w3.org/2001/XMLSchema#string

Mitchell P Levesque

http://www.w3.org/2001/XMLSchema#string

Nancy K Pryer

http://www.w3.org/2001/XMLSchema#string

William R Sellers

http://www.w3.org/2001/XMLSchema#string

P2860

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Mutations of the BRAF gene in human cancer

Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation

Clonal evolution in cancer

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

P2888

P304

251-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

578296

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE11814

http://www.w3.org/2001/XMLSchema#string

P407

P433

7436

http://www.w3.org/2001/XMLSchema#string

P478

494

http://www.w3.org/2001/XMLSchema#string

P50

Reinhard Dummer

P577

2013-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234098511

http://www.w3.org/2001/XMLSchema#string

P6179

1017875293

http://www.w3.org/2001/XMLSchema#string

P698

23302800

http://www.w3.org/2001/XMLSchema#string

P932

3930354

http://www.w3.org/2001/XMLSchema#string